Next-Generation HIV Antiretroviral Therapy and Vaccine Candidates
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 13080
Interests: virology; HIV Vaccine; clinical immunology
2. International Research Center of Medical Sciences (IRCMS), Kumamoto University, Kumamoto 860-8555, Japan
Interests: HIV vaccines; vaccine vectors, clinical trials; pre-clinical models; T cells
Despite many years of research, a successful vaccine or cure for HIV-1 remains among the highest priority areas of unmet need in infectious disease. The vaccine development path for the HIV-1 pathogen has been extremely challengin for different reasons, one of them being the pathogen’s high antigenic variability and immune evasion. Its high mutation rate allows it to evade immune responses by modifying its target immunogens during the course of infection. The development of safe, effective, and scalable therapeutic strategies to control viral replication in HIV-infected individuals in the absence of daily antiretroviral drugs is pivotal, and new vaccine strategies rely on our ability to identify the challenges posed by this pathogen. Understanding the pathogenesis and correlates of protection for this disease, and our ability to accurately direct immune responses and to vaccinate specific populations are such examples of these roadblocks. However, there are also some important translational science issues that need to be addressed. Therefore, I would like to encourage the submission of papers to this Special Issue that focus on novel approaches to vaccine development, including vaccine immunology, passive therapies, and genetic vaccination. Additionally, results from ongoing human vaccine clinical trials will also be integrated into this Special Issue. Moreover, being focused on a cure for HIV will address the problem of viral latency and how it is controlled and will emphasize cure-related human clinical trials.
With the view of their global health importance, adding new recent information on these subjects may elicit and identify areas of future investigation and collectively generate the knowledge required to design better vaccines, treatment methods, and networks that will facilitate transformative approaches to prevention and cure for this disease.
Dr. H.M. Manukumar
Prof. Tomas Hanke
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- antiretroviral therapy
- HIV vaccine
- neutralizing antibodies
- protein vaccines
- combination regimens